<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4601">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231230</url>
  </required_header>
  <id_info>
    <org_study_id>20060346</org_study_id>
    <nct_id>NCT01231230</nct_id>
  </id_info>
  <brief_title>Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway</brief_title>
  <official_title>Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of an inhaled long-acting beta-adrenergic agonist to an inhaled
      glucocorticosteroid improves disease control in persistent asthma. This observation has
      supported the use of long-acting beta-adrenergic agonist/glucocorticosteroid combination
      preparations for the management of asthma. Currently, salmeterol/fluticasone and
      formoterol/budesonide are available for clinical use. The long-term beneficial clinical
      effects of the two drug classes seem to be synergistic, and several mechanisms of
      glucocorticoid-beta-adrenergic agonist interactions involving gene transcription have been
      invoked to explain this phenomenon.This study, wish to address the question whether
      glucocorticoids can acutely potentiate the bronchodilator response to a long-acting
      beta-adrenergic agonist.We expect that in patients with asthma, the short-term
      bronchodilator effect of salmeterol is enhanced by the addition of fluticasone, which by
      itself has no short-term bronchodilator effect. To test this premise, we will assess the
      respective short-term effects of salmeterol (50 µg), fluticasone (250 µg),
      salmeterol/fluticasone (50/250 µg), and placebo/placebo on spirometric parameters. Airway
      Blood flow will also be measured to ensure that vasoconstriction does not occur.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fourteen lifetime nonsmokers with a physician diagnosis of asthma will be recruited for the
      study. All subjects will be allowed to use short-acting beta-adrenergic agonists as rescue
      medication.

      Inclusion criteria:

        1. Males and females, 18 to 65 years of age.

        2. FEV1 60-85% of predicted on the screening day.

      Exclusion criteria:

        1. Women of childbearing potential who do not use accepted birth control measures;
           pregnant and breast feeding women.

        2. Cardiovascular disease and/or use of cardiovascular medications

      2. Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance 4. Acute
      respiratory infection within four weeks prior to the study 5. Use, within two weeks prior to
      the study, of any anti-asthma medication not mentioned above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Maximum Change From Baseline in Airway Blood Flow (Qaw)</measure>
    <time_frame>maximum change in Qaw within 240 minutes post drug inhalation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>overal study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants were treated with either fluticasone/salmeterol, fluticasone,salmeterol in random order on different days separated by at least 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo inhalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants were treated with placebo in random order on different days of the experimental drug as controls separated by at least 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone</intervention_name>
    <description>220- mcg once</description>
    <arm_group_label>overal study</arm_group_label>
    <other_name>flovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo inhalation</intervention_name>
    <description>placebo inhalation once</description>
    <arm_group_label>placebo inhalation</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>50 mcg salmeterol once</description>
    <arm_group_label>overal study</arm_group_label>
    <other_name>serevent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone/salmeterol</intervention_name>
    <description>inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol</description>
    <arm_group_label>overal study</arm_group_label>
    <other_name>advair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, 18 to 65 years of age.

          2. FEV1 60-85% of predicted on the screening day. -

        Exclusion Criteria:

        1. Women of childbearing potential who do not use accepted birth control measures;
        pregnant and breast feeding women. 2. Cardiovascular disease and/or use of cardiovascular
        medications 3. Subjects with known beta-adrenergic agonist or glucocorticosteroid
        intolerance 4. Acute respiratory infection within four weeks prior to the study 5. Use,
        within two weeks prior to the study, of any anti-asthma medication not mentioned above
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Wanner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>December 3, 2014</lastchanged_date>
  <firstreceived_date>October 25, 2010</firstreceived_date>
  <firstreceived_results_date>March 24, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Wanner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>asthma, corticosteroids, bronchodilator, airway blood flow</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone, salmeterol drug combination</mesh_term>
    <mesh_term>Salmeterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from our Asthma Database. Subjects with asthma who are in our database have previously agreed to serve as potential subjects in future studies. These subjects have signed an informed consent (approved by UM IRB) to be included in this database.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Groups</title>
          <description>inhalation of 250 mcg of fluticasone
fluticasone: 220- mcg once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Fluticasone</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Salmeterol</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Fluticasone/Salmeterol</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fourteen lifetime nonsmokers with a physician diagnosis of asthma were recruited for the study. All but one of the subjects were using an ICS/LABA combination preparation regularly, and all used a short-acting b2-adrenergic agonist as rescue medication. All subjects had to have a prebronchodilator FEV1 of 60% to 85% predicted .</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>participant received in random order one of the four treatments ( fluticasone, salmeterol, fluticasone+salmeterol or placebo)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Airway blood flow (Qaw)</title>
          <description>Qaw was measured with a previously validated soluble inert gas uptake method. It is based on quantifying the disappearance of the soluble gas dimethylether (DME) from the anatomical dead space. The method involves the inhalation of a gas mixture containing 10 % DME and 90% nitrogen from 500 ml below the total lung capacity position to total lung capacity, followed by a breathhold (5 or 15 sec) and subsequent exhalation while the instantaneous concentrations of DME and nitrogen are recorded.</description>
          <units>µl.min-1.ml-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.8" spread="2.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Change From Baseline in Airway Blood Flow (Qaw)</title>
        <time_frame>maximum change in Qaw within 240 minutes post drug inhalation</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>inhalation of 250 mcg of fluticasone
fluticasone: 220- mcg once</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inhalation of placebo diskus
placebo inhalation: placebo inhalation once</description>
          </group>
          <group group_id="O3">
            <title>Salmeterol</title>
            <description>inhalation of salmeterol 50 mcg once
Salmeterol: 50 mcg salmeterol once
Salmeterol: 50 mcg once</description>
          </group>
          <group group_id="O4">
            <title>Fluticasone/Salmeterol</title>
            <description>inhalation of fluticasone 250mcg combined with salmeterol 50 mcg
fluticasone/salmeterol: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Change From Baseline in Airway Blood Flow (Qaw)</title>
            <units>change from baseline ( µl/min/ml)</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-11.0" spread="2.9"/>
                  <measurement group_id="O2" value="14.1" spread="1.9"/>
                  <measurement group_id="O3" value="23.9" spread="3.6"/>
                  <measurement group_id="O4" value="25.5" spread="4.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>mean difference from baseline relative to placebo</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>mean difference from baseline relative to placebo</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>mean difference from baseline relative to placebo</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone</title>
          <description>inhalation of 250 mcg of fluticasone
fluticasone: 220- mcg once</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>inhalation of placebo diskus
placebo inhalation: placebo inhalation once</description>
        </group>
        <group group_id="E3">
          <title>Salmeterol</title>
          <description>inhalation of salmeterol 50 mcg once
Salmeterol: 50 mcg salmeterol once
Salmeterol: 50 mcg once</description>
        </group>
        <group group_id="E4">
          <title>Fluticasone/Salmeterol</title>
          <description>inhalation of fluticasone 250mcg combined with salmeterol 50 mcg
fluticasone/salmeterol: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Wanner, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305)243-2568</phone>
      <email>awanner@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
